1160247-07-3

Basic information

• Product Name: tert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate
• Synonyms: tert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate;3-Oxo-1-oxa-4,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester;ert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate;3-oxo-1-Oxa-4,9-diazaspiro[5.5]undecane-9-carboxylic acid 1,1-dimethylethyl ester;1-Oxa-4,9-diazaspiro[5.5]undecane-9-carboxylic acid, 3-oxo-, 1,1-dimethylethyl ester
• CAS NO: 1160247-07-3
• Molecular Formula: C₁₃H₂₂N₂O₄
• Molecular Weight: 270.32478
• Mol File: 1160247-07-3.mol

Chemical Properties

• Boiling Point: 454.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.18±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.87±0.20(Predicted)
• CAS DataBase Reference: tert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate(1160247-07-3)
• EPA Substance Registry System: tert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate(1160247-07-3)

Safety Data

• Hazardous Substances Data: 1160247-07-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Tert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate is used as a building block in organic synthesis for constructing more complex molecules. Its versatile structure allows for the creation of a wide range of compounds with diverse properties and applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate is used as a potential drug candidate. Its unique structure and pharmacological properties make it a promising candidate for the development of new therapeutic agents.
Used in the Study of Spirocyclic Compounds:
The spirocyclic structure of tert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate makes it a valuable tool for researchers studying the properties and behavior of spirocyclic compounds. This knowledge can be applied to the design and synthesis of new compounds with specific characteristics and applications.
Used in Pharmaceutical Industry:
Tert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate is used as a key intermediate in the synthesis of pharmaceutical compounds. Its unique structure and reactivity enable the development of novel drugs with improved efficacy and selectivity.
Used in Chemical Research:
In the realm of chemical research, tert-Butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate serves as a model compound for studying the synthesis, properties, and reactions of spirocyclic systems. This research can lead to a better understanding of the underlying principles governing the behavior of such compounds and inspire the design of new molecules with specific functions.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 41661-47-6 piperidin-4-one 
• 819800-93-6 tert-butyl 4-hydroxy-4-(nitromethyl)-piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 147804-30-6 1-oxa-6-aza-spiro-[2.5]octane-6-caboxylic acid tert-butyl ester 
• 392331-66-7 4-aminomethyl-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 930785-40-3 1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylic acid tert-butyl ester 
• 1352926-03-4 tert-butyl 4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate 

Relevant articles and documents

HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS

The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or sa

1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS

The present invention provides, in part, compounds of Formula I and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to compounds of general formula (I) having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain. (formula 1) wherein Y is (formula 2) or (formula 3) ? n is 1 or 2; ? q is 1, 2, 3, 4, 5 or 6; ? X is a bond, -C(O)O-, -C(0)NR 8-, -C(O)-, -0- or -C(R 4R 4.)-; ? R 1is C(0)R 5or S(O) 2R 5.

The discovery of new spirocyclic muscarinic M3 antagonists

The optimisation of a new series of high potency muscarinic M3 antagonists, derived from high throughput screening library hit is described.